Specht E E
West J Med. 1980 Oct;133(4):297-303.
Fractures of the hip have been shown to have a significant personal and societal impact in Western countries; this impact is largely borne by elderly women, and represents a substantial health care commitment in modern society. For many people a fracture of the proximal end of the femur represents a preterminal event of considerable cost, both in economic loss and psychosocial well-being. These fractures are generally recognized as a clinical complication of osteoporosis, and are one index of general skeletal fragility which is also manifested in fractures of the vertebrate and of the distal radius (Colles fracture). There is increasing evidence that hormonal deprivation in elderly women is directly related to loss of skeletal integrity and consequent fragility. There is also increasing evidence that hormonal substitution is effective in preventing this structural loss and fragility. Unfortunately, a therapeutic dilemma has arisen in that the preparation that seems to give optimal protection, conjugated estrogens, has also been reported to cause an increased incidence of endometrial carcinoma. The search for a preparation or dosage regimen of estrogens which simultaneously prevents skeletal atrophy and fragility and avoids the increased risk of malignancy must be a long-term goal.
在西方国家,髋部骨折已被证明会对个人和社会产生重大影响;这种影响主要由老年女性承担,并且在现代社会中代表着一项重大的医疗保健投入。对许多人来说,股骨近端骨折意味着一个代价高昂的临终前事件,无论是在经济损失还是心理社会福祉方面。这些骨折通常被认为是骨质疏松症的临床并发症,并且是一般骨骼脆弱性的一个指标,这种脆弱性也表现在脊椎骨折和桡骨远端骨折(科勒斯骨折)中。越来越多的证据表明,老年女性体内的激素缺乏与骨骼完整性丧失及随之而来的脆弱性直接相关。也有越来越多的证据表明,激素替代疗法在预防这种结构丧失和脆弱性方面是有效的。不幸的是,出现了一个治疗困境,即似乎能提供最佳保护的制剂——结合雌激素,也被报道会导致子宫内膜癌发病率增加。寻找一种既能同时预防骨骼萎缩和脆弱性又能避免恶性肿瘤风险增加的雌激素制剂或给药方案必定是一个长期目标。